Dose-dependent effects of adjunctive treatment with aripiprazole on hyperprolactinemia induced by risperidone in female patients with schizophrenia

Journal of Clinical Psychopharmacology

Volumn 30, Issue 5, 2010, Pages 596-599

  Yasui Furukori, Norio ^a   Furukori, Hanako ^a,b   Sugawara, Norio ^a,c   Fujii, Akira ^a   Kaneko, Sunao ^a  

^a HIROSAKI UNIVERSITY   (Japan)

^b Department of Psychiatry   (Japan)

^c Hirosaki Aiseikai Hospital   (Japan)

Author keywords

aripiprazole; dose effects; prolactin; risperidone

Indexed keywords

ARIPIPRAZOLE; BIPERIDEN; DIAZEPAM; FLUNITRAZEPAM; PROLACTIN; RISPERIDONE; SENNOSIDE;

ADJUVANT CHEMOTHERAPY; ADULT; AMENORRHEA; ARTICLE; AUTONOMIC DYSFUNCTION; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFECT; FEMALE; HUMAN; HYPERPROLACTINEMIA; MENTAL DISEASE; NEUROLOGIC DISEASE; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; SCHIZOPHRENIA; SEXUAL DYSFUNCTION; TREATMENT OUTCOME;

ADULT; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; HYPERPROLACTINEMIA; MIDDLE AGED; PIPERAZINES; PROLACTIN; QUINOLONES; RISPERIDONE; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 77957252761     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/JCP.0b013e3181ee832d     Document Type: Article

References (28)

1. Byerly M, Suppes T, Tran QV, et al. Clinical implications of antipsychotic-induced hyperprolactinemia in patients with schizophrenia spectrum or bipolar spectrum disorders: recent developments and current perspectives. J Clin Psychopharmacol. 2007;27: 639-661. (Pubitemid 351339452)
2. Bostwick JR, Guthrie SK, Ellingrod VL. Antipsychotic-induced hyperprolactinemia. Pharmacotherapy. 2009;29: 64-73.
3. Meaney AM, Smith S, Howes OD, et al. Effects of long-term prolactin-raising antipsychotic medication on bone mineral density in patients with schizophrenia. Br J Psychiatry. 2004;184: 503-508. (Pubitemid 38725710)
4. Schotte A, Bonaventure P, Janssen PFM, et al. In vitro receptor binding and in vivo receptor occupancy in rat and guinea pig brain: risperidone compared with antipsychotic hitherto used. Jpn J Pharmacol. 1995;69: 399-412. (Pubitemid 26013775)
5. Shiwach RS, Carmody TJ. Prolactogenic effects of risperidone in male patientsVa preliminary study. Acta Psychiatr Scand. 1998;98: 81-83.
6. Caracci G, Ananthamoorthy R. Prolactin levels in premenopausal women treated with risperidone compared with those of women treated with typical neuroleptics. J Clin Psychopharmacol. 1999;19: 194-196. (Pubitemid 29161974)
7. David SR., Taylor CC, Kinon, BJ, et al. The effects of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophrenia. Clin Ther. 2000;22: 1085-1096.
8. Cada DJ, Levien T, Baker DE. Aripiprazole. Hosp Pharmacy. 2003;38: 247-256. (Pubitemid 36330903)
9. Casey DE, Carson WH, Saha AR, et al. Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study. Psychopharmacology. 2003;166: 391-399.
10. Marder SR, McQuade RD, Stock E, et al. Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebocontrolled trials. Schizophr Res. 2003;61: 123-136. (Pubitemid 36513927)
11. Kane JM, Carson WH, Saha AR, et al. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry. 2002;63: 763-771.
12. Lin SK, Chen CK. Reversal of antipsychotic-induced hyperprolactinemia, weight gain, and dyslipidemia by aripiprazole: a case report. J Clin Psychiatry. 2006;67: 1307.
13. Wahl R, Ostroff R. Reversal of symptomatic hyperprolactinemia by aripiprazole. Am J Psychiatry. 2005;162: 1542-1543.
14. Lee BH, Kim YK, Park SH. Using aripiprazole to resolve antipsychotic-induced symptomatic hyperprolactinemia: a pilot study. Prog Neuropsychopharmacol Biol Psychiatry. 2006;30: 714-717.
15. Wolf J, Fiedler U. Hyperprolactinemia and amenorrhea associated with olanzapine normalized after addition of aripiprazole. J Clin Pharm Ther. 2007;32: 197-198. (Pubitemid 46449704)
16. Shim JC, Shin JG, Kelly DL, et al. Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: a placebo-controlled trial. Am J Psychiatry. 2007;164: 1404-1410.
17. Chen CH, Huang MC, Lu ML. Aripiprazole resolves symptomatic hyperprolactinemia in a male schizophrenic patient. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32: 893-894.
18. Lu ML, Shen WW, Chen CH. Time course of the changes in antipsychotic-induced hyperprolactinemia following the switch to aripiprazole. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32: 1978-1981.
19. Mir A, Shivakumar K, Williamson RJ, et al. Change in sexual dysfunction with aripiprazole: a switching or add-on study. J Psychopharmacol. 2008;22: 244-253. (Pubitemid 351847447)
20. Sheldrick AJ, Gründer G. Aripiprazole reduces serum prolactin in a woman with prolactinoma and acute psychosis. Pharmacopsychiatry. 2008;41: 160.
21. Byerly MJ, Marcus RN, Tran QV, et al. Effects of aripiprazole on prolactin levels in subjects with schizophrenia during cross-titration with risperidone or olanzapine: analysis of a randomized, open-label study. Schizophr Res. 2009;107: 218-222.
22. Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13: 261-276. (Pubitemid 18039085)
23. Lingjaerde O, Ahlfors UG, Bech P, et al. The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand Suppl. 1987;334: 1-100. (Pubitemid 17115352)
24. Lindenmayer JP, Bernstein-Hyman R, Grochowski S, et al. Psychopathology of schizophrenia: initial validation of a 5-factor model. Psychopathology. 1995;28: 22-31. (Pubitemid 24368666)
25. Shapiro DA, Renock S, Arrington E, et al. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology. 2003;28: 1400-1411. (Pubitemid 41070874)
26. Kuroki T, Meltzer HY, Ichikawa J. Effects of antipsychotic drugs on extracellular dopamine levels in rat medial prefrontal cortex and nucleus accumbens. J Pharmacol Exp Ther. 1999;288: 774-781. (Pubitemid 29119694)
27. Gründer G, Fellows C, Janouschek H, et al. Brain and plasma pharmacokinetics of aripiprazole in patients with schizophrenia: an [18F]fallypride PET study. Am J Psychiatry. 2008;165: 988-995.
28. Urichuk L, Prior TI, Dursun S, et al. Metabolism of atypical antipsychotics: involvement of cytochrome p450 enzymes and relevance for drug-drug interactions. Curr Drug Metab. 2008;9: 410-418. (Pubitemid 352025195)